Physician profile
Leslie E Diaz
NPI 1750342689
$11,476.07
in general payments reported to CMS, 2019-2025
34 companies · $1,518 in 2025
The $1,518 reported for 2025 was more than what 83% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,217 · 2020: $2,133 · 2021: $1,507 · 2022: $1,663 · 2023: $1,365 · 2024: $1,073 · 2025: $1,518.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,956.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,956.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $3,979.20 | 2019-2023 | Symtuza |
| Viiv Healthcare Company | $3,063.08 | 2019-2025 | Cabenuva, Dovato, Apretude |
| Gilead Sciences, INC. | $1,768.18 | 2019-2025 | Biktarvy |
| Insmed, INC. | $319.92 | 2019-2025 | Arikayce, Brinsupri |
| Merck Sharp & Dohme LLC | $258.47 | 2019-2025 | Zerbaxa |
| Astellas Pharma US INC | $200.13 | 2019-2020 | |
| Theratechnologies INC. | $192.53 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $176.30 | 2020 | |
| Tetraphase Pharmaceuticals, INC. | $132.97 | 2019-2020 | |
| Allergan, INC. | $124.31 | 2019-2020 | |
| Livanova USA, INC. | $122.20 | 2019 | |
| Madrigal Pharmaceuticals | $102.29 | 2024 | Rezdiffra |
| Janssen Products, LP | $99.00 | 2020 | |
| Abbvie INC. | $98.47 | 2019-2023 | Teflaro |
| Exact Sciences Corporation | $92.91 | 2023-2025 | Cologuard Collection Kit |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cumberland Pharmaceuticals, INC. | $92.60 | 2019-2020 | |
| Nabriva Therapeutics, Plc | $74.29 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $71.18 | 2019-2021 | |
| Amarin Pharma, INC. | $62.32 | 2019-2020 | |
| Napo Pharmaceuticals INC | $54.52 | 2019 | |
| Paratek Pharmaceuticals, INC. | $51.66 | 2019-2025 | Nuzyra |
| Antares Pharma, INC. | $45.68 | 2019-2020 | |
| Melinta Therapeutics, LLC | $43.44 | 2019 | |
| Shire North American Group INC | $41.88 | 2019 | |
| Argenx US, INC. | $32.80 | 2025 | Vyvgart Hytrulo |
| Cipla USA INC. | $30.17 | 2021 | |
| Janssen Scientific Affairs, LLC | $23.98 | 2023 | Symtuza |
| Smith+Nephew, INC. | $21.83 | 2019 | |
| Mylan Pharmaceuticals INC. | $18.68 | 2019 | |
| Pfizer INC. | $18.10 | 2019 | |
| Hologic Sales and Service, LLC | $16.31 | 2023 | Thinprep 2000 Processor, Aptima |
| Astrazeneca Pharmaceuticals LP | $16.09 | 2019 | |
| Glaxosmithkline, LLC. | $15.65 | 2024 | Arexvy, Shingrix |
| Redhill Biopharma INC. | $14.93 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leslie Diaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.